Zeneca quashes rumours of Roche bid
Friday 04 August 1995
Market whispers had put the two companies together in a concerted campaign that had seen the pharmaceutical group's shares gyrate wildly in recent weeks. Yesterday's unequivocal denial of talks, which analysts believed could have led to a pounds 15bn bid by the giant Swiss group, saw Zeneca's shares fall 23p to 1,097p.
David Barnes, chief executive refused to comment further on bid talks as he announced a 44 per cent jump in pre-tax profits for the six months to June to pounds 506m. Despite the good figures, the market also worried about comments from Mr Barnes suggesting a slowdown in profits growth in the second half thanks to the cost of promoting new drugs.
He said: "We continue to face highly competitive markets in all our businesses. The group faces the exciting and demanding challenge of launching an unusually large number of new products. I am confident the returns from this near- term revenue investment programme will help secure Zeneca's future growth."
The big improvement in profits partly reflected a pounds 100m charge in the previous year's figures to fund a restructuring of Zeneca's speciality and agrochemicals businesses. Underlying profits were 12 per cent better after a 6 per cent rise in sales from pounds 2.38bn to pounds 2.53bn.
That included pharmaceuticals sales, which exceeded pounds 1bn for the first time in a six-month period as a 7 per cent volume increase was offset by a 1 per cent decline in prices as cuts, especially in Italy, continued to squeeze the industry.
Zeneca's older drugs, such as Tenormin, fell but the shortfall was more than made up by newer treatments. Sales of Diprivan, an anaesthetic, and cancer drug Zoladex grew at 21 per cent and 33 per cent respectively.
In Zeneca's other divisions, strong demand for herbicides drove a 17 per cent rise in profits from the agrochemicals operation. Rising raw materials prices squeezed the small speciality chemicals arm.
The company also remained tight-lipped about prospects for expanding its latest acquisition - 50 per cent of Salick, a US company that runs cancer clinics. Analysts believe the provision of care will be a profitable sideline for drugs companies, which face increasing pricing pressures in their core business.
Zeneca is, however, seen as less dependent on diversifications than many of its peers. It has a widely admired new drugs pipeline, including four treatments for cancer and a pill for asthma.
- 1 Exclusive: Abusers using spyware apps to monitor partners reaches 'epidemic proportions'
- 2 Margaret Thatcher 'expressed fears of Asian rising' at Anglo-Irish summit in 1984
- 3 Sussex couple die in suspected Christmas Day 'suicide pact'
- 4 The 'Black Museum': After 150 years, public set to see exhibits from police’s grisly crime museum
- 5 The Unluckiest People of the Year 2014 (and one very unlucky giraffe)
British actor Idris Elba cannot star as James Bond because he is black, says shock jock Rush Limbaugh
Germany anti-Islam protests: 17,000 march on Dresden against 'Islamification of the West'
Ukip member gets into Christmas spirit with Union Flag plea to Santa 'for our country back'
Immigrants make UK racist, says Ukip councillor Trevor Shonk
BBC director Danny Cohen: Rising UK antisemitism makes me feel more uncomfortable than ever
Katie Hopkins speaks out on childhood obesity: 'Parents of fat children should be prosecuted for child cruelty'
iJobs Money & Business
Not specified: Selby Jennings: VP/SVP Credit Quant Top tier investment bank i...
Not specified: Selby Jennings: Quantitative Research | Global Equity | New Yor...
Not specified: Selby Jennings: SVP Model Validation This top tiered investment...
Highly Competitive: Selby Jennings: Our client, a leading European Oil trading...